IP Library Granted Patent US 11,181,528
Granted Patent B2
US 11,181,528 · App. 16/225,669 · Granted Nov 23, 2021

Assays for detecting modified compounds

Inventors: Elazar Rabbani (New York, NY); Jannis G. Stavrianopoulos (Bay Shore, NY); Joshua Rabbani (New York, NY); Praveen Pande (Holbrook, NY)
Assignee: Enzo Life Sciences, Inc.
G01N33/6803C12Q1/485G01N33/92C12Y207/01091C12Y207/11001G01N2405/08G01N2410/00G01N2440/14G01N2440/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,181,528
App. No.
16/225,669
Granted
Nov 23, 2021
Kind
B2
Abstract

Provided are methods and compositions which are useful for separating, isolating, detecting, and quantifying compounds of interest which have been modified chemically, enzymatically or catalytically from other compounds which have not been so modified. The modifications may take the form of functional groups which are gained, lost or retained by the compounds of interest.

Claims (21)

1. A method for detecting or quantifying an activity in a sample that causes a compound to gain a functional group, the method comprising the steps of:

(a) providing:

(i) a compound which can gain a functional group, the compound comprising at least one non-radioactive signaling moiety;

(ii) a chemical source of the functional group which can be gained by the compound; and

(iii) a sample;

wherein the compound is a lipid, and

wherein the functional group is a glycosyl group;

(b) forming a mixture comprising the compound, the source of the functional group and the sample, and incubating the mixture under conditions suitable for the compound to gain the functional group; and

(c) capturing any compound that has gained the functional group on a matrix comprising a glycosyl group-binding lectin and separating said compound which has gained the functional group from any compound which has not gained the functional group; and

(d) detecting or quantifying the non-radioactive signaling moiety of any captured separated compounds having the functional group, thereby detecting or quantifying the activity in the sample.

2. The method of claim 1 , wherein the non-radioactive signaling moiety comprises a fluorescent compound, a phosphorescent compound, a chemiluminescent compound, a chromogenic compound, a chelating compound, an electron dense compound, a magnetic compound, an energy transfer member or pair, an intercalating compound, an antibody, an antigen, a hapten, a receptor, a hormone, a ligand or an enzyme, or any combination thereof.

3. A method for detecting or quantifying an activity in sample which removes a functional group from a compound, the method comprising the steps of:

(a) providing:

(i) a compound comprising a functional group and at least one non-radioactive signaling moiety; and

(ii) a sample;

wherein the compound is a lipid, and

wherein the functional group is a glycosyl group;

(b) forming a mixture comprising the compound and the sample and incubating the mixture under conditions suitable for the compound to lose the functional group; and

(c) capturing on a matrix comprising a glycosyl group-binding lectin and separating any compound that has the functional group following the incubation from any compound which has lost the functional group; and

(d) detecting or quantifying the non-radioactive signaling moiety of any captured separated compounds having the functional group, thereby detecting or quantifying the activity in the sample.

4. The method of claim 3 , wherein the non-radioactive signaling moiety comprises a fluorescent compound, a phosphorescent compound, a chemiluminescent compound, a chromogenic compound, a chelating compound, an electron dense compound, a magnetic compound, an energy transfer member or pair, an intercalating compound, an antibody, an antigen, a hapten, a receptor, a hormone, a ligand or an enzyme, or any combination thereof.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2023
From: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
To: ENZO BIOCHEM, INC.; ENZO CLINICAL LABS, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP; ENZO LIFE SCIENCES, INC.
Reel/Frame 064369/0031 →
SECURITY INTEREST Recorded Apr 3, 2023
From: ENZO LIFE SCIENCES, INC.; ENZO CLINICAL LABS, INC.; ENZO BIOCHEM, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP
To: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
Reel/Frame 063239/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2019
From: RABBANI, ELAZAR; RABBANI, JOSHUA; PANDE, PRAVEEN; STAVRIANOPOULOS, JANNIS G.
To: ENZO LIFE SCIENCES, INC.
Reel/Frame 047985/0249 →
Continuity (4)
Continuation 15195343 · Jun 28, 2016
Continuation 14296756 · Jun 5, 2014
Division 12806950 · Aug 24, 2010
Related Publication 20190162733A1 · May 30, 2019